Senseonics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 04:46 pm EDT
Share
Senseonics Holdings, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 4.13 million compared to USD 3.71 million a year ago. Revenue was USD 4.13 million compared to USD 3.71 million a year ago. Net loss was USD 20.42 million compared to net income of USD 104.23 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to basic earnings per share from continuing operations of USD 0.22 a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.03 a year ago.
For the six months, sales was USD 8.26 million compared to USD 6.2 million a year ago. Revenue was USD 8.26 million compared to USD 6.2 million a year ago. Net loss was USD 19.1 million compared to net income of USD 190.95 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to basic earnings per share from continuing operations of USD 0.42 a year ago. Diluted loss per share from continuing operations was USD 0.04 compared to USD 0.06 a year ago.
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.
SENSEONICS HOLDINGS, INC. 
